Identification of hot spots within druggable binding regions by computational solvent mapping of proteins

Journal of Medicinal Chemistry

Volumn 50, Issue 6, 2007, Pages 1231-1240

  Landon, Melissa R ^a   Lancia Jr , David R ^c   Yu, Jessamin ^a   Thiel, Spencer C ^c   Vajda, Sandor ^b  

^a BOSTON UNIVERSITY   (United States)

^b Boston University   (United States)

^c Solmap Pharmaceuticals Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ASPARTIC PROTEINASE; BACTERIAL ENZYME; KETOPANTOATE REDUCTASE; OXIDOREDUCTASE; PROTEIN DERIVATIVE; RENIN; UNCLASSIFIED DRUG;

ALGORITHM; ARTICLE; BINDING SITE; DRUG STRUCTURE; ENERGY; ESCHERICHIA COLI; NONHUMAN; PREDICTION; PROTEIN ANALYSIS; PROTEIN CONFORMATION; STRUCTURE ANALYSIS;

ALCOHOL OXIDOREDUCTASES; ALGORITHMS; AMIDES; BINDING SITES; COMPUTERS, MOLECULAR; DRUG DESIGN; ESCHERICHIA COLI PROTEINS; FUMARATES; MAGNETIC RESONANCE SPECTROSCOPY; MODELS, MOLECULAR; MOLECULAR CONFORMATION; PROTEIN BINDING; PROTEINS; RENIN; THERMODYNAMICS;

EID: 33947658802     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm061134b     Document Type: Article

References (52)

1. DeLano, W. L. Unraveling hot spots in binding interfaces: Progress and challenges. Curr. Opin. Struct. Biol. 2002, 12, 14-20.
2. Kortemme, T.; Baker, D. A simple physical model for binding energy hot spots in protein-protein complexes. Proc. Natl. Acad. Sci. U.S.A. 2002, 99, 14116-14121.
3. Hajduk, P. J.; Huth, J. R.; Fesik, S. W. Druggability indices for protein targets derived from NMR-based screening data. J. Med. Chem. 2005, 48, 2518-2525.
4. Ciulli, A.; Williams, G.; Smith, A. G.; Blundell, T. L.; Abell, C. Probing hot spots at protein-ligand binding sites: A fragment-based approach using biophysical methods. J. Med. Chem. 2006, 49, 4992-5000.
5. Dennis, S.; Kortvelyesi, T.; Vajda, S. Computational mapping identifies the binding sites of organic solvents on proteins. Proc. Natl. Acad. Sci. U.S.A. 2002, 99, 4290-4295.
6. Kortvelyesi, T.; Dennis, S.; Silberstein, M.; Brown, L., III; Vajda, S. Algorithms for computational solvent mapping of proteins. Proteins 2003, 51, 340-351.
7. Silberstein, M.; Dennis, S.; Brown, L.; Kortvelyesi, T.; Clodfelter, K.; Vajda, S. Identification of substrate binding sites in enzymes by computational solvent mapping. J. Mol. Biol. 2003, 332, 1095-1113.
8. Mattos, C.; Bellamacina, C. R.; Peisach, E.; Pereira, A.; Vitkup, D.; Petsko, G. A.; Ringe, D. Multiple solvent crystal structures: Probing binding sites, plasticity, and hydration. J. Mol. Biol. 2006, 357, 1471-1482.
9. Mattos, C.; Ringe, D. Locating and characterizing binding sites on proteins. Nat. Biotechnol. 1996, 14, 595-599.
10. Mattos, C.; Ringe, D. Proteins in organic solvents. Curr. Opin. Struct. Biol. 2001, 11, 761-764.
11. Bohm, H. J. The computer program LUDI: A new method for the de novo design of enzyme inhibitors. J. Comput.-Aided Mol. Des. 1992, 6, 61-78.
12. Goodford, P. J. A computational procedure for determining energetically favorable binding sites on biologically important macromolecules. J. Med. Chem. 1985, 28, 849-857.
13. Lawrence, M. C.; Davis, P. C. CLIX: A search algorithm for finding novel ligands capable of binding proteins of known three-dimensional structure. Proteins 1992, 12, 31-41.
14. Miranker, A.; Karplus, M. Functionality maps of binding sites: A multiple copy simultaneous search method. Proteins 1991, 11, 29-34.
15. Laurie, A. T.; Jackson, R. M. Q-SiteFinder: An energy-based method for the prediction of protein-ligand binding sites. Bioinformatics 2005, 21, 1908-1916.
16. Cavasotto, C. N.; Orry, A. J.; Abagyan, R. A. Structure-based identification of binding sites, native ligands, and potential inhibitors for G-protein coupled receptors. Proteins 2003, 51, 423-433.
17. Raman, V. K.; Lee, Y. A.; Lindpaintner, K. The cardiac renin-angiotensin-aldosterone system and hypertensive cardiac hypertrophy. Am. J. Cardiol. 1995, 76, 18D-23D.
18. Stanton, A. Potential of renin inhibition in cardiovascular disease. JRAAS 2003, 4, 6-10.
19. Staffileno, B. A. Treating hypertension with cardioprotective therapies: The role of ACE inhibitors, ARBs, and beta-blockers. J. Cardiovasc. Nurs. 2005, 20, 354-364.
20. Simoneau, B.; Lavallee, P.; Anderson, P. C.; Bailey, M.; Bantle, G.; Berthiaume, S.; Chabot, C.; Fazal, G.; Halmos, T.; Ogilvie, W. W.; Poupart, M. A.; Thavonekham, B.; Xin, Z.; Thibeault, D.; Bolger, G.; Panzenbeck, M.; Winquist, R.; Jung, G. L. Discovery of non-peptidic P2-P3 butanediamide renin inhibitors with high oral efficacy. Bioorg. Med. Chem. 1999, 7, 489-508.
21. Tong, L.; Pav, S.; Lamarre, D.; Simoneau, B.; Lavallee, P.; Jung, G. Crystallographic studies on the binding modes of P2-P3 butanediamide renin inhibitors. J. Biol. Chem. 1995, 270, 29520-29524.
22. Wood, J. M.; Maibaum, J.; Rahuel, J.; Grutter, M. G.; Cohen, N. C.: Rasetti, V.; Ruger, H.; Goschke, R.; Stutz, S.; Fuhrer, W.; Schilling, W.; Rigollier, P.; Yamaguchi, Y.; Cumin, F.; Baum, H. P.; Schnell, C. R.; Herold, P.; Mah, R.; Jensen, C.; O'Brien, E.; Stanton, A.; Bedigian, M. P. Structure-based design of aliskiren, a novel orally effective renin inhibitor. Biochem. Biophys. Res. Commun. 2003, 308, 698-705.
23. Allikmets, K. Aliskiren (Speedel). Curr. Opin. Invest. Drugs 2002, 3, 1479-1482.
24. Rahuel, J.; Rasetti, V.; Maibaum, J.; Rueger, H.; Goschke, R.; Cohen, N. C.; Stutz, S.; Cumin, F.; Fuhrer, W.; Wood, J. M.; Grutter, M. G. Structure-based drug design: The discovery of novel nonpeptide orally active inhibitors of human renin. Chem. Biol. 2000, 7, 493-504.
25. Ciulli, A.; Abell, C. Biophysical tools to monitor enzyme-ligand interactions of enzymes involved in vitamin biosynthesis. Biochem. Soc. Trans. 2005, 33, 767-771.
26. Begley, T. P.; Kinsland, C.; Strauss, E. The biosynthesis of coenzyme A in bacteria. Vitam. Horm. 2001, 61, 157-171.
27. Dennis, S.; Vajda, S. Semiglobal simplex optimization and its application to determining the preferred solvation sites of proteins. J. Comput. Chem. 2002, 23, 319-334.
28. Gilson, M. K.; Honig, B. Calculation of the total electrostatic energy of a macromolecular system: solvation energies, binding energies, and conformational analysis. Proteins 1988, 4, 7-18.
29. Zhang, C.; Cornette, J. L.; Delisi, C. Consistency in structural energetics of protein folding and peptide recognition. Protein Sci. 1997, 6, 1057-1064.
30. Schaefer, M.; Karplus, M. A Comprehensive analytical treatment of continuum electrostatics. J. Phys. Chem. 1996, 100, 1578-1599.
31. Brooks, B. R.; Bruccoleri, R. E.; Olafson, B. D.; States, D. J.; Swaminathan, S.; Karplus, M. Charmm-A program for macromolecular energy, minimization, and dynamics calculations. J. Comput. Chem. 1983, 4, 187-217.
32. Verdonk, M. L.; Cole, J. C.; Hartshorn, M. J.; Murray, C. W.; Taylor, R. D. Improved protein-ligand docking using GOLD. Proteins 2003, 52, 609-623.
33. Jones, G.; Willett, P.; Glen, R. C.; Leach, A. R.; Taylor, R. Development and validation of a genetic algorithm for flexible docking. J. Mol. Biol. 1997, 267, 727-748.
34. McDonald, I. K.; Thornton, J. M. Satisfying hydrogen bonding potential in proteins. J. Mol. Biol. 1994, 238, 777-793.
35. Rahuel, J.; Priestle, J. P.; Grutter, M. G. The crystal structures of recombinant glycosylated human renin alone and in complex with a transition state analog inhibitor. J. Struct. Biol. 1991, 107, 227-236.
36. Sali, A.; Veerapandian, B.; Cooper, J. B.; Moss, D. S.; Hofmann, T.; Blundell, T. L. Domain flexibility in aspartic proteinases. Proteins 1992, 12, 158-170.
37. Liu, G. Protein tyrosine phosphatase 1B inhibition: Opportunities and challenges. Curr. Med. Chem. 2003, 10, 1407-1421.
38. Shuker, S. B.; Hajduk, P. J.; Meadows, R. P.; Fesik, S. W. Discovering high-affinity ligands for proteins: SAR by NMR. Science 1996, 274, 1531-1534.
39. Hu, Y.; Qiao, L.; Wang, S.; Rong, S. B.; Meuillet, E. J.; Berggren, M.; Gallegos, A.; Powis, G.; Kozikowski, A. P. 3-(Hydroxymethyl)-bearing phosphatidylinositol ether lipid analogues and carbonate surrogates block PI3-K. Akt, and cancer cell growth. J. Med. Chem. 2000, 43, 3045-3051.
40. Thomas, C. C.; Deak, M.; Alessi, D. R.; van Aalten, D. M. High-resolution structure of the pleckstrin homology domain of protein kinase b/akt bound to phosphatidylinositol (3,4,5)-trisphosphate. Curr. Biol. 2002, 12, 1256-1262.
41. Hajduk, P. J.; Dinges, J.; Schkeryantz, J. M.; Janowick, D.; Kaminski, M.; Tufano, M.; Augeri, D. J.; Petros, A.; Nienaber, V.; Zhong, P.; Hammond, R.; Coen, M.; Beutel, B.; Katz, L.; Fesik, S. W. Novel inhibitors of Erm methyltransferases from NMR and parallel synthesis. J. Med. Chem. 1999, 42, 3852-3859.
42. Schluckebier, G.; Zhong, P.; Stewart, K. D.; Kavanaugh, T. J.; Abad-Zapatero, C. The 2.2 A structure of the rRNA methyltransferase ErmC′ and its complexes with cot'actor and cofactor analogs: Implications for the reaction mechanism. J. Mol. Biol. 1999, 289, 277-291.
43. Kussie, P. H.; Gorina, S.; Marechal, V.; Elenbaas, B.; Moreau, J.; Levine, A. J.; Pavletich, N. P. Structure of the MDM2 oncoprotein bound to the p53 tumor suppressor transactivation domain. Science 1996, 274, 948-953.
44. Skarzynski, T.; Mistry, A.; Wonacott, A.; Hutchinson, S. E.; Kelly, V. A.; Duncan, K. Structure of UDP-N-acetylglucosamine enolpyruvyl transferase, an enzyme essential for the synthesis of bacterial peptidoglycan, complexed with substrate UDP-N-acetylglucosamine and the drug fosfomycin. Structure 1996, 4, 1465-1474.
45. Liu, G.; Xin, Z.; Liang, H.; Abad-Zapatero, C.; Hajduk, P. J.; Janowick, D. A.; Szczepankiewicz, B. G.; Pei, Z.; Hutchins, C. W.; Ballaron, S. J.; Stashko, M. A.; Lubben, T. H.; Berg, C. E.; Rondinone, C. M.; Trevillyan, J. M.; Jirousek, M. R. Selective protein tyrosine phosphatase IB inhibitors: Targeting the second phosphotyrosine binding site with noncarboxylic acid-containing ligands. J. Med. Chem. 2003, 46, 3437-3440.
46. Szczepankiewicz, B. G.; Liu, G.; Hajduk, P. J.; Abad-Zapatero, C.; Pei, Z.; Xin, Z.; Lubben, T. H.; Trevillyan, J. M.; Stashko, M. A.; Ballaron, S. J.; Liang, H.; Huang, F.; Hutchins, C. W.; Fesik, S. W.; Jirousek, M. R. Discovery of a potent, selective protein tyrosine phosphatase 1B inhibitor using a linked-fragment strategy. J. Am. Chem. Soc. 2003, 125, 4087-4096.
47. Dunten, P.; Kammlott, U.; Crowther, R.; Levin, W.; Foley, L. H.; Wang, P.; Palermo, R. X-ray structure of a novel matrix metalloproteinase inhibitor complexed to stromelysin. Protein Sci. 2001, 10, 923-926.
48. Dhanaraj, V.; Ye, Q. Z.; Johnson, L. L.; Hupe, D. J.; Ortwine, D. F.; Dunbar, J. B., Jr.; Rubin, J. R.; Pavlovsky, A.; Humblet, C.; Blundell, T. L. X-ray structure of a hydroxamate inhibitor complex of stromelysin catalytic domain and its comparison with members of the zinc metalloproteinase superfamily. Structure 1996, 4, 375-386.
49. Pavlovsky, A. G.; Williams, M. G.; Ye, Q. Z.; Ortwine, D. F.; Purchase, C. F., II; White, A. D.; Dhanaraj, V.; Roth, B. D.; Johnson, L. L.; Hupe, D.; Humblet, C.; Blundell, T. L. X-ray structure of human stromelysin catalytic domain complexed with nonpeptide inhibitors: Implications for inhibitor selectivity. Protein Sci. 1999, 8, 1455-1462.
50. Hajduk, P. J.; Boyd, S.; Nettesheim, D.; Nienaber, V.; Severin, J.; Smith, R.; Davidson, D.; Rockway, T.; Fesik, S. W. Identification of novel inhibitors of urokinase via NMR-based screening. J. Med. Chem. 2000, 43, 3862-3866.
51. Crump, M. P.; Ceska, T. A.; Spyracopoulos, L.; Henry, A.; Archibald, S. C.; Alexander, R.; Taylor, R. J.; Findlow, S. C.; O'Connell, J.; Robinson, M. K.; Shock, A. Structure of an allosteric inhibitor of LFA-1 bound to the I-domain studied by crystallography, NMR, and calorimetry. Biochemistry 2004, 43, 2394-2404.
52. Liu, G.; Huth, J. R.; Olejniczak, E. T.; Mendoza, R.; DeVries, P.; Leitza, S.; Reilly, E. B.; Okasinski, G. F.; Fesik, S. W.; von Geldern, T. W. Novel p-arylthio cinnamides as antagonists of leukocyte function-associated antigen-1/intracellular adhesion molecule-1 interaction. 2. Mechanism of inhibition and structure-based improvement of pharmaceutical properties. J. Med. Chem. 2001, 44, 1202-1210.